Effects of valsartan combined with statins on blood glucose, blood lipids, HGF and PPAR-γ in patients with diabetes and coronary heart disease

YAO Fei; YU Qiurong; GONG Ye; KONG Yinghong

doi:10.3969/j.issn.1671-6450.2018.07.004

Abstract：Objective To investigate the effect of valsartan combined with statin on blood glucose,blood lipid,HGF and PPAR-γ in patients with coronary heart disease. Methods Ninety patients with coronary disease and diabetes were chose from February 2015 to February 2017. According to the digital random table method, they were divided into two groups. Pa-tients in the control group were treated with valsartan. Patients in the observation group were treated with rosuvastatin on the basis of the control group. The effect of blood glucose, blood lipid, HGF and PPAR-γ levels in each group before and after treatment were detected. Results There were no significant differences in FPG and 2hPG between the two groups before treat-ment(t=1. 734, P=0. 163; t=1. 832, P=0. 279; t=1. 453, P=0. 108; t=1. 143, P=0. 124). There was no significant difference in the blood lipid levels between the two groups before treatment (P＞0. 05). After treatment, the blood lipid levels of both groups were significantly improved (P＜0. 05). The levels of TC, TG and LDL-C in the observation group were signif-icantly lower than those in the control group (t=6. 365, P=0. 000; t=6. 354, P=0. 000; t=6. 225, P=0. 000). HDL-C in the observation group was significantly higher than that in the control group (t=6. 465, P=0. 000). There was no signifi-cant difference in HGF and PPAR-γ levels between the two groups before treatment( t=0. 745, P=0. 276; t=0. 257, P=0. 740). After treatment, the two indexes in both groups were significantly improved (P＜0. 05). After treatment,the levels of HGF in the observation group were significantly lower than that in the control group,and PPAR-γ level was significantly higher than that in the control group (t=7. 274, P=0. 000; t=11. 457, P=0. 000). Conclusion Combination with valsar-tan and statins, lipid levels in patients with diabetes and coronary heart disease are more effectively regulated by PPAR-γ .